A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
NCT03798106
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
46
Enrollment
OTHER
Sponsor class
Conditions
Sarcoma
Interventions
DRUG:
Durvalumab, pazopanib
Sponsor
Yonsei University